Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.59 |
| ▸ | PPARA | Q07869 | 10/20 | 0.59 |
| ▸ | PPARG | P37231 | 8/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3906389 | 0.93 | PPARD (0.57) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL3912669 | 0.90 | PPARD (0.61) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL3908574 | 0.87 | PPARD (0.59) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL3915373 | 0.84 | FFAR1 (0.56) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL3906954 | 0.83 | PPARG (0.60) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL3901298 | 0.82 | PPARG (0.56) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL3916667 | 0.81 | PPARG (0.58) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL3107388 | 0.81 | PPARD (0.58) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL4676727 | 0.81 | PPARG (0.67) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL3905482 | 0.81 | FFAR1 (0.60) | PPARDPPARAPPARGFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | PPARD 214/4885PPARA 294/4885PPARG 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.